Top Stories
At the midpoint of their respective proposed ranges, Latigo would raise $272 million while BlossomHill would pocket $125 million.
Lantheus shareholders will receive $102.50 per share in cash at closing, along with contingent value rights (CVRs) that could provide up to an additional $12 per share.
The alliance pairs enzymatic peptide engineering with physics-based AI modeling.
Oelkers succeeds founder Ugur Sahin as the company expands beyond its mRNA success into late-stage oncology.
The agreements will resolve all US federal or state governmental claims, as well as class actions, related to generic antitrust litigation against Sandoz.
Conference News
COM701 MAIA-ovarian trial progressing as planned with median progression-free survival data from the interim analysis expected by Q1 2027Trial-in-progress poster on MAIA-ovarian presented at the ESMO ...
- First patients dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers- On track for interim results reporting in 2H 2026HOUSTON, July 31, 2026 /PRNewswire/ -- FibroBiologics, I...
Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026CHAPEL HILL, N.C., July 31, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax T...
HANGZHOU, China, July 31, 2026 /PRNewswire/ -- CellOrigin, a biotechnology company focused on next-generation in vivo and in vitro cell therapy technologies, has announced two major progresses in both...
Novel, fast-acting, non-scheduled peptide analgesic addresses the military priority for effective, non-addictive battlefield pain controlKISSIMMEE, Fla.--(BUSINESS WIRE)--PVP Labs, a clinical-stage bi...
